Boston, MA — June 13, 2022 — Elarex Inc. is pleased to announce that they have been selected to participate in the Canadian Technology Accelerator (CTA) in Boston, a highly competitive program run by the Consulate General of Canada that will feature 10 innovative companies. This cohort represents exciting developments in the sectors of Biotechnology, Digital Health, Medical Technology and more.
“Participation in this program will allow Elarex to accelerate our impact within the Boston-area biotech marketplace and sharpen our company strategy with the help of seasoned biotech executive mentors.”, says Robert DeWitte, CEO and Co-Founder of Elarex. “This program is another great example of the support Elarex has received from multiple levels of government in Canada, including funding from NRC IRAP, equity investment from Ontario Centre of Innovation and grants flowing to our academic partners at McMaster University through both the NSERC I2I program and FedDev Ontario’s SOPHIE initiative.”
“We are excited to have Elarex join the Boston CTA program. They bring tremendous Canadian innovation to US and beyond – imagine a new world where vaccines will not need a cold chain for storage and transportation!”, says Serban Georgescu, MD, Manager of the Boston Canadian Technology Accelerator.
The Canadian Technology Accelerator runs from May to November and pairs small companies with highly accomplished mentors who provide guidance and expertise in navigating the Boston biotech market. The official announcement from the Consulate General of Canada can be found here.
Elarex Inc. is helping vaccine manufacturers escape the cold chain which can help them by reducing spoilage; improving the stability of new vaccine candidates; and by making LMIC markets more accessible when cold chain infrastructure is unreliable or unavailable.
The solution is a very straightforward, patented mixture of natural products that are considered safe by the US FDA and do not require freeze drying. Many types of vaccines, small molecules, enzymes, biologics, DNA and mRNA-LNPs have all been shown to benefit from the stabilization offered by our technology.
Elarex Inc. is a privately held company, incorporated in Ontario, Canada.
For more information, press only:
Brent Lefebvre, firstname.lastname@example.org
For more information on Product: